Cipla has announced the launch of Ciplostem, a pioneering cell-based regenerative therapy for Knee Osteoarthritis (OA), marking a breakthrough in India’s orthobiologic treatment ecosystem. Approved by the Drug Controller General of India (DCGI), the therapy provides a disease-modifying solution for Grade II and Grade III OA patients, offering long-term relief compared to standard symptomatic care.
A New Chapter in Orthobiologic Innovation
Developed in collaboration with Stempeutics Research, Ciplostem represents Cipla’s entry into advanced cell-based medicine. The launch addresses a significant gap in India’s OA management, where most therapies—including painkillers, injections and physiotherapy—primarily focus on short-term symptom control rather than slowing disease progression.
India is among the worst affected countries globally, with millions facing mobility challenges, declining joint function and poor quality of life due to degenerative knee disease.
Why Ciplostem Matters for India
- Over 48 million Indians currently suffer from Knee Osteoarthritis
- Increasing cases among younger working-age adults
- Existing treatments lack durable benefits and may lead to early knee replacement surgery
Ciplostem aims to delay or prevent surgical intervention, enhancing joint longevity and reducing dependency on pain medication.
How the Therapy Works
Ciplostem is administered as a single intra-articular injection directly into the knee joint.
Key clinical actions include:
✔ Reducing inflammation
✔ Relieving chronic pain
✔ Preserving cartilage and improving joint lubrication
✔ Enhancing mobility and quality of life
Clinical outcomes suggest benefits lasting up to two years, positioning Ciplostem as a promising long-term solution in the OA treatment pathway.
Exam-Oriented Facts
- Ciplostem is India’s first DCGI-approved cell-based therapy for Grade II–III Knee Osteoarthritis
- Developed by Cipla with Stempeutics Research
- Single-dose intra-articular injection with benefits lasting up to two years
- Targets growing OA burden affecting 48M+ people in India
Share this Article with your friends :
Discover more from Srishti IAS
Subscribe to get the latest posts sent to your email.
